Document is current
Any future updates will be listed below
-
Authors
Singh, Jasvinder A. http://orcid.org/0000-0003-3485-0006
Cleveland, John D.
-
Funding
Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
- License Information
-
More Information
Article History
Received: 15 March 2018
Accepted: 6 November 2018
First Online: 14 November 2018
Ethics approval and consent to participate
: The University of Alabama at Birmingham’s Institutional Review Board approved this study and waived the need for informed consent for this database study. All investigations were conducted in conformity with ethical principles of research.
: Not applicable
: JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals, Inc. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS served as a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. DC has no conflicts to declare. There are no non-financial competing interests for any of the authors.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
